“When was the last time that America’s chair industry hiked the price of chairs 400% and suddenly nobody in the country could afford to sit down?” Funny, isn’t it, how these episodes keep happening in a sector of the economy where a new competitor, before being allowed to enter even a well-understood generic market, faces the prospect of unpredictable and expensive government denials and delays? [Scott Alexander]
More: Scott Gottlieb on how the new, more ardently regulatory FDA keeps generic drugs (and devices) off the market. Don’t blame the patent angle; EpiPen is off-patent [Timothy Holbrook, The Conversation]
Comments are closed.